Salesforce
CRM
Apple
AAPL
Microsoft
MSFT
Coinbase
COIN
Meta Platforms
META
US Stock MarketDetailed Quotes
APVO Aptevo Therapeutics
- 5.630
- -4.380-43.76%
Close Dec 12 16:00 ET
- 6.000
- +0.370+6.57%
Pre 08:43 ET
2.82MMarket Cap-0.01P/E (TTM)
14.900High5.300Low6.49MVolume11.480Open10.010Pre Close70.89MTurnover1367.45%Turnover Ratio0.00P/E (Static)500.33KShares399.60052wk High0.64P/B2.67MFloat Cap5.10652wk Low--Dividend TTM474.90KShs Float144729.200Historical High--Div YieldTTM95.90%Amplitude5.106Historical Low10.915Avg Price1Lot Size
About Aptevo Therapeutics Company
Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.
Company Profile
SymbolAPVO
Company NameAptevo Therapeutics
Listing DateJul 20, 2016
Issue Price3.71
Founded2016
CEOMr. Marvin L. White
MarketNASDAQ
Employees40
Fiscal Year Ends12-31
Address2401 4th Avenue,Suite 1050
CitySeattle
ProvinceWashington
CountryUnited States of America
Zip Code98121
Phone1-206-838-0500
Company Executives
- Name
- Position
- Salary
- Marvin L. White
- Director, President and Chief Executive Officer
- 1.17M
- Daphne L. Taylor
- Senior Vice President, Chief Financial Officer and Principal Accounting Officer
- --
- Jeffrey G. Lamothe
- Executive Vice President and Chief Operating Officer
- 944.00K
- So Young Kwon
- Senior Vice President, Corporate Affairs and Business Development and General Counsel
- 775.52K
- Dr. John E. Niederhuber, M.D.
- Chairman of the Board
- 102.09K
- Grady Grant, III
- Independent Director
- 77.30K
- Daniel J. Abdun-Nabi
- Independent Director
- 79.59K
- Barbara Lopez Kunz
- Independent Director
- 87.93K
- Dr. Zsolt Harsanyi,PhD
- Independent Director
- 96.26K
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.